A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone
| Autor: | Bartosz Korczowski, Tanya O'Neal, Alena Jandourek, H. David Friedland, Christopher R. Cannavino, Sheldon L. Kaplan, John S. Bradley, Agnes Nemeth |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
Methicillin-Resistant Staphylococcus aureus Microbiology (medical) Staphylococcus aureus Pediatrics medicine.medical_specialty Adolescent medicine.disease_cause 03 medical and health sciences 0302 clinical medicine Community-acquired pneumonia 030225 pediatrics Streptococcus pneumoniae Pneumonia Bacterial polycyclic compounds medicine Humans Ceftaroline fosamil Prospective Studies 030212 general & internal medicine Child Infusions Intravenous Prospective cohort study Cephalosporin Antibiotic business.industry Ceftriaxone Bacterial pneumonia Infant medicine.disease Anti-Bacterial Agents Cephalosporins Community-Acquired Infections Hospitalization Pneumonia Treatment Outcome Infectious Diseases Child Preschool Pediatrics Perinatology and Child Health Female business medicine.drug |
| Zdroj: | Pediatric Infectious Disease Journal. 35:752-759 |
| ISSN: | 0891-3668 0153-0763 |
| Popis: | Community-acquired bacterial pneumonia (CABP) remains a major infection among children, despite the use of pneumococcal vaccination. Ceftaroline fosamil is a broad-spectrum cephalosporin antibiotic with activity against many bacteria, including Streptococcus pneumoniae (both penicillin-nonsusceptible and multidrug-resistant strains) and Staphylococcus aureus (including methicillin-resistant S. aureus). This article describes the safety, tolerability, and effectiveness of ceftaroline fosamil in the treatment of pediatric patients hospitalized with CABP, from a randomized, active-controlled, observer-blinded clinical study (registration number NCT01530763).Pediatric patients were stratified into 4 age cohorts and randomized (3:1) to receive either intravenous ceftaroline fosamil or ceftriaxone, with optional oral switch for a total treatment duration of 5-14 days. Enrollment was planned for 160 patients. Data collected included demographics, infection characteristics and pathogens. Treatment-emergent adverse events, clinical outcomes, and microbiologic responses were assessed.Ceftaroline fosamil was well tolerated. Similar percentages of patients in the ceftaroline fosamil (55/121; 45%) and ceftriaxone (18/39; 46%) groups reported treatment-emergent adverse events. Coombs seroconversion was observed in 17% of patients in the ceftaroline fosamil group; however, no evidence of hemolytic anemia or hemolysis was found. No deaths were reported during the study. Ceftaroline fosamil had similar effectiveness to ceftriaxone, with high clinical cure rates at test-of-cure in the modified intent-to-treat population (94/107; 88% and 32/36; 89%, respectively). Three documented S. aureus infections were successfully treated in the ceftaroline group, including one caused by methicillin-resistant S. aureus.The results of this study suggest that ceftaroline fosamil may be an important treatment option for pediatric patients hospitalized with CABP. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|